Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
March 04 2026
Vimseltinib
ASCPT 2026

Exposure-Response Analyses for Vimseltinib in Patients With Tenosynovial Giant Cell Tumor

March 05 2026
Vimseltinib
ASCPT 2026

Population Pharmacokinetic Analyses of Vimseltinib in Healthy Volunteers and Patients With Solid Tumors or Tenosynovial Giant Cell Tumor

Subscribe to ASCPT 2026
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement
  • Compliance Hotline
  • Consent Manager

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top